CALA stock forecast
Our latest prediction for Calithera Biosciences, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 4.07$.
In the short term (2weeks), CALA's stock price should outperform the market by 1.20%. During that period the price should oscillate between -10.60% and +13.25%.
In the medium term (3months), CALA's stock price should underperform the market by -4.71%. During that period the price should oscillate between -27.99% and +30.59%.Get email alerts
Create a solid portfolio with CALA
About Calithera Biosciences, Inc.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
At the moment the company generates 22M USD in revenues.
On its last earning announcement, the company reported a loss of -1.67$ per share.
The book value per share is 4.09$
Three months stock forecastNov. 20, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|